Search
for
Sort by
Research
300-330 / 1000+ results
research Response to comments on the Scientific Opinion on the substantiation of a health claim related to spermidine and prolongation of the growing phase (anagen) of the hair cycle pursuant to Article 13(5) of Regulation (EC) No 1924/2006
The EFSA maintained its view that spermidine's effect on hair growth is related to disease treatment and does not meet the health claim criteria.
research Salute to Surgeon of the Month
The document's conclusion cannot be provided because the document cannot be parsed.
research 708 SIG-1451: A topical anti-inflammatory new chemical entity for atopic dermatitis (AD)
SIG-1451 could be a promising new treatment for atopic dermatitis.
research Exploring the clinical implications of novel SRD5A2 variants in 46,XY disorders of sex development
New SRD5A2 variants may disrupt protein function, aiding diagnosis and treatment of related disorders.
research Price Wars
I'm sorry, but I can't provide a conclusion without the content of the document. Please provide the text you'd like summarized.
research Kudos
The document cannot be understood or processed.
research Disorders of Hair
The document's conclusion cannot be provided because the document is not readable or understandable.
research Follow-up
research Erratum
research Finasteride-related suicidal ideation reported to Lareb
research ABHRS Profile
The document's conclusion cannot be summarized because the content is not accessible or understandable.
research Disorders of Hair
The document's conclusion cannot be provided because the document is not readable or understandable.
research A Statistical Study of Dermatoses(1995-1999)
The document's conclusion cannot be provided because the document is not accessible or understandable.
research Examination of Clinical and Demographic Characteristics of 14 Cases with Frontal Fibrosing Alopecia
The document's conclusion cannot be provided as the content is not available for parsing.
research ERRATUM
research Society and Forum Separate Financially
The document's conclusion cannot be summarized because the content is not available.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
research 609 Topical Sandalore®, a specific OR2AT4-stimulating odorant, ameliorates female telogen effluvium: Randomized, double-blinded, placebo-controlled clinical trial
Sandalore®, a synthetic scent, improved hair loss and satisfaction in women with telogen effluvium.
research Outgoing ABHRS President’s Corner
The document's content could not be processed.
research Self-Emulsifying Drug Delivery Systems (SEDDS): Measuring Energy Dynamics to Determine Thermodynamic and Kinetic Stability
Solidified SEDDS improve drug stability and bioavailability better than liquid SEDDS.
research Subject Index
The document's conclusion cannot be summarized because the content is not accessible or understandable.
research 10.1063/5.0132123.1
research Patient welfare
The document's conclusion cannot be determined.
research Notes from the Editors Emeritus
I'm sorry, but I can't provide a summary without the content of the document.
research HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond
Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.
research Barcelona Update
The document's conclusion cannot be summarized because the content is not accessible.
research Topical odorant application of the specific olfactory receptor OR2AT4 agonist, Sandalore®, improves telogen effluvium‐associated parameters
Sandalore® improves hair growth and quality in people with hair loss.
research Negative term supplementary protection certificates granted by UK Intellectual Property Office
The UK Intellectual Property Office allows granting of supplementary protection certificates with negative terms.